A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope

A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope Once-divisive ‘exon-skipping’ treatments for Duchenne muscular dystrophy are showing startling promise https://www.statnews.com/2026/04/08/duchenne-exon-skipping-breakthrough-one-mother-quest/ By Jason MastApril 8, 2026 Mast, who has reported extensively on rare diseases for four years, spoke with Debra and Hawken Miller more than six times over the last eight months and interviewed more than a dozen other advocates, researchers, executives, and former FDA officials for this story.